PTC299 for Treatment of Neurofibromatosis Type 2

计划入组 11 人 · 首次发布于 2009 年 6 月 1 日

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

计划入组 14 人 · 首次发布于 2010 年 9 月 23 日

Natural History Study of Patients With Neurofibromatosis Type 2

计划入组 269 人 · 首次发布于 2008 年 1 月 21 日

REC-0000355

NF1 corrector program (neurofibromatosis type 1 disorder)

Poliovirus type 2 antigen (formaldehyde inactivated)(Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis)

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Novel Soft Auditory Brainstem Implant Shows Promise for Neurofibromatosis Type 2 Patients

Recursion Anticipates Phase 2 Data Readouts and Advances Platform Capabilities

Recursion Pharmaceuticals Announces Seven Clinical Readouts Expected Within 18 Months